Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabilized patients post acute coronary syndromes
• Determine whether aliskiren reduces the levels of NT-proBNP from baseline to week 8 as compared to placebo. • Determine whether valsartan reduces the levels of NT-proBNP from baseline to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin
To assess the efficacy of pasireotide LAR in pancreatic and duodenum NETs (Insulinoma, Gastrinoma, VIPoma, and Glucagonoma) based on disease specific primary biochemical tumor markers.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary artery disease when added to optimal background therapy
To evaluate the effect of aliskiren 300 mg, in addition to optimized background therapy, compared to placebo on progression of coronary atherosclerosis (defined as change from baseline in percent athe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
An exploratory, multi-centre, double-blind, placebo-controlled crossover study, to investigate the bronchodilatory efficacy of a single dose of indacaterol in fixed combination with mometasone furoate delivered via a MDDPI (Twisthaler®) in adult patients with persistent asthma using open label Seretide® Accuhaler® (50/250 mcg b.i.d.) as an active control
To evaluate the bronchodilatory efficacy, in terms of trough FEV1, of indacaterol (500 μg) in combination with mometasone furoate (400 μg) delivered as 2 inhalations of QMF149 (indacaterol 250 μg/mome...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 diabetes
To demonstrate the effect of 4 week treatment with vildagliptin compared to placebo on the glucagon counterregulatory response to hypoglycemia in patients with T2DM, assessed as mean glucagon level (A...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)
To determine whether treatment with RAD001 10 mg/d plus best supportive care prolongs the progression free survival (PFS) compared to treatment with Placebo plus best supportive care in patients with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A 10 week, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of once daily dosing of aliskiren (300 mg qd) to twice daily dosing of aliskiren (150 mg bid) in patients with essential hypertension
The primary objective of the study is: To compare the efficacy of aliskiren 300 mg qd to aliskiren 150 mg bid in reducing 24-hour mean ambulatory diastolic blood pressure (MADBP) from baseline to the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of seasonal allergic rhinitis
• To assess the induction of sustained tolerance to allergen when VAK694 with a dosing regimen given every 4 weeks for a total of 4 doses is combined with subcutaneous immunotherapy for the treatment ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
Open label, phase II study to evaluate efficacy and safety of oral nilotinib in Philadelphia positive (Ph+) chronic myelogenous leukemia (CML) pediatric patients
1. To assess efficacy of nilotinib in pediatric patients with Ph+ CML-CP resistant or intolerant to either imatinib or dasatinib 2. To assess efficacy of nilotinib in pediatric patients with Ph+ CML-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
An eight-week, randomized, double-blind, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren 300 mg in comparison with valsartan 320 mg in patients with mild to moderate hypertension during exercise after a missed dose
To demonstrate that aliskiren 300 mg monotherapy exerts a greater blunting effect than valsartan 320 mg by assessing the rise in SBP at peak exercise (85% of the maximal predicted heart rate) and comp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
16
17
18
19
20
21
22
23
24
25
Suivant